Senior housing analysts report on rising SNF coronavirus cases … Paxlovid antiviral COVID-19 pill appears to be effective against omicron … Nearly half of American adults have gained weight during...
NIH: COVID rebound after Paxlovid may signal a strong immune response
By
Alicia Lasek
Oct 11, 2022
Patients who had rebound symptoms after taking Paxlovid showed a more robust immune response to SARS-CoV-2 than patients with no rebound, investigators reported.
Clinical briefs for Thursday, Dec. 1
By
Alicia Lasek
Dec 01, 2022
Drug overdoses in seniors climb between 2000 and 2020 … Predictive clinical tool determines 5, 9 and 13-year risk of dementia … Remdesivir and corticosteroids tied to better COVID acute-care outcomes...
Clinical briefs for Tuesday, May 3
By
Alicia Lasek (f3)
May 03, 2022
Paxlovid does not prevent COVID-19, new trial data show … Black and white patients have had similar risk of MS for decades, study finds … Parkinson’s drug hopeful found safe in early clinical trial...
CDC: Turn to Paxlovid to treat COVID-19, not steroids or antibiotics
By
Alicia Lasek (f3)
Apr 26, 2022
The agency is urging clinicians to consider the now readily available, recommended therapies such as Paxlovid as first-line COVID-19 treatments.
Pfizer says final data show COVID-19 pill stays strong against severe illness
Dec 14, 2021
Latest results show that drug cuts hospitalizations, deaths by nearly 90 percent when taken within three to five days of the start of symptoms
Stanford to test antiviral pills as long COVID treatment
By
Alicia Lasek
Nov 28, 2022
Investigators plan to test whether the antiviral drug Paxlovid will relieve symptoms of the syndrome known as long COVID, also called post-acute sequelae of COVID-19.